Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

A broad look at the historical use of proteasome inhibitor therapy in patients with multiple myeloma centered on 3 agents: bortezomib, carfilzomib, and ixazomib.

Shared insight on how real-world experience and data with proteasome inhibitors in multiple myeloma compare to what was seen in clinical trials.

Expert perspectives on data from the TOURMALINE-MM1 trial, which tested ixazomib therapy in patients with relapsed/refractory multiple myeloma.

Experts Paul Richardson, MD, and Cristina Gasparetto, MD, discuss trial data analyzing the in-class transition from bortezomib to ixazomib for patients with multiple myeloma.

Reflections on the patient-reported adherence and outcome data with IRd (ixazomib, lenalidomide, dexamethasone) therapy after an in-class transition from bortezomib to ixazomib for patients with multiple myeloma.

Insight on the ASH 2021 update highlighting response rates and discontinuation in patients who received in-class transition from bortezomib to ixazomib for multiple myeloma.

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

Expert perspectives on recent updates in the use of proteasome inhibitors for patients with multiple myeloma.